(Adnkronos) - “Necessario un corretto uso dei farmaci già disponibili e crearne di nuovi. Per il futuro al G7 parleremo di incentivare la ricerca di nuovi antibiotici. E per farlo l’Italia proporrà incentivi “push”, che favoriscono la ricerca, e “pull”, che garantiscono agli antibiotici fondamentali che arrivassero in futuro un mercato che altrimenti non ci sarebbe” . Lo ha detto Guido Rasi, professore ordinario di Microbiologia e microbiologia clinica presso Università degli Studi di Roma Tor Vergata, già direttore esecutivo, European Medicines Agency (Ema) e consulente del ministro della Salute, partecipando al talk ‘Antimicrobico resistenza. La sfida di investire in ricerca’, disponibile nei canali web e social di Adnkronos.
Category
🗞
NewsTranscript
00:00To try to defeat or slow down the antibiotic resistance, we have two
00:08versions. One, the current one, that is, to best use the current weapons, the
00:14current antibiotics, and the other one, to produce new ones. On the first
00:19side, the very important thing is to have a holistic approach, the so-called
00:25One Health. In this, the Italian government is far ahead, they have already achieved
00:30good results with surveillance and with a continuous campaign of correct use.
00:39As for the future, we will talk about it later in the G7 area, they are a whole
00:44series of measures to be able to always encourage, in a
00:50universal approach as possible, the research of new antibiotics and new
00:56remedies. Italy, in my opinion, will present in the G7 a very interesting program.
01:02As we know, there are two types of, even here we have two types of aspects. One
01:08promotes the research of innovation, the other promotes the possibility that this
01:16is sustainable, because the antibiotic market is in crisis. The Italian government
01:25is preparing two measures in this sense, of course they will be much more effective
01:29if they are in alignment with other global initiatives.
01:35And what are the policy proposals that you intend to introduce to address the issue of
01:38antimicrobial resistance?
01:40Basically, to join the large funding from the so-called PUSH incentives, that is, those
01:47that promote the research of innovation, and then find within, instead of the Italian
01:55pharmaceutical spending, the incentives for the so-called PUL, that is, those for which
02:02fundamental antibiotics that arrive in the future can be used at their best, while guaranteeing
02:10a market that otherwise would not exist. These two measures will certainly be presented
02:16during the G7 in October.